Q: Who should NOT take Calcii dobesilas monohydricus?

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Q: Can Calcii dobesilas monohydricus be used during pregnancy?

Pregnancy Data on the use of calcium dobesilate in pregnant women are limited. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of calcium dobesilate during pregnancy. Breast-feeding Calcium dobesilate passes into breast milk in negligible amounts (0.4 µg/ml after a dose of 3 × 500 mg). Doxium 500 is not intended for use during breast-feeding. As a precautionary measure, either t

Q: What precautions should be taken with Calcii dobesilas monohydricus?

In cases of severe renal impairment requiring dialysis, the dose may be reduced. In very rare cases, administration of calcium dobesilate may cause agranulocytosis (see section 4.8). In such cases, symptoms may include high fever, oral cavity infections (tonsillitis), sore throat, anogenital inflammation, and other signs typical of infection. If any of these symptoms occur, treatment must be discontinued. A complete blood count and leukogram should then be performed immediately. Doxium 500 may t

Q: Who manufactures Calcii dobesilas monohydricus?

Przedsiębiorstwo Produkcji Farmaceutycznej HASCO-LEK S.A. (Polska)

Question 1

What is Calcii dobesilas monohydricus used for?

Accepted Answer

Microangiopathy, particularly diabetic retinopathy.
Clinical manifestations of chronic venous insufficiency of the lower limbs (pain, cramps, paraesthesia, swelling, venostasis, dermatosis). Post-thrombotic syndrome, microcirculatory disorders of venous origin.
Haemorrhoids.
This medicinal product is intended for adult patients.

Question 2

How does Calcii dobesilas monohydricus work?

Accepted Answer

Pharmacotherapeutic group: venoactive agent, antivaricose drug
ATC code: C05BX01
Calcium dobesilate acts on the capillary walls by correcting their impaired physiological functions — increased permeability and decreased resistance.

Question 3

What is the active ingredient in Calcii dobesilas monohydricus?

Accepted Answer

Calcii dobesilas monohydricus (Calcii dobesilas monohydricum)

Question 4

What pharmaceutical form is Calcii dobesilas monohydricus available in?

Accepted Answer

Calcii dobesilas monohydricus: Tabletki powlekane 500 mg (doustna)

Question 5

Is Calcii dobesilas monohydricus OTC or prescription only?

Accepted Answer

Calcii dobesilas monohydricus is available over-the-counter (OTC) — no prescription required.

Question 6

What are the side effects of Calcii dobesilas monohydricus?

Accepted Answer

Adverse reactions are listed below in accordance with the MedDRA convention by system organ class and frequency:
Very common (≥1/10)
Common (≥1/100 to <1/10)
Uncommon (≥1/1,000 to <1/100)
Rare (≥1/10,000 to <1/1,000)
Very rare (<1/10,000)
Not known (cannot be estimated from the available data)
Blood and lymphatic system disorders
Very rare: agranulocytosis (see section 4.4)
Not known: neutropenia, leukopenia
Immune system disorders
Uncommon: hypersensitivity (rash, allergic dermatitis, pruritus,

Question 7

Who should NOT take Calcii dobesilas monohydricus?

Accepted Answer

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Question 8

Can Calcii dobesilas monohydricus be used during pregnancy?

Accepted Answer

Pregnancy
Data on the use of calcium dobesilate in pregnant women are limited.
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of calcium dobesilate during pregnancy.
Breast-feeding
Calcium dobesilate passes into breast milk in negligible amounts (0.4 µg/ml after a dose of 3 × 500 mg). Doxium 500 is not intended for use during breast-feeding. As a precautionary measure, either t

Question 9

What precautions should be taken with Calcii dobesilas monohydricus?

Accepted Answer

In cases of severe renal impairment requiring dialysis, the dose may be reduced.
In very rare cases, administration of calcium dobesilate may cause agranulocytosis (see section 4.8). In such cases, symptoms may include high fever, oral cavity infections (tonsillitis), sore throat, anogenital inflammation, and other signs typical of infection. If any of these symptoms occur, treatment must be discontinued. A complete blood count and leukogram should then be performed immediately.
Doxium 500 may t

Question 10

Who manufactures Calcii dobesilas monohydricus?

Accepted Answer

Przedsiębiorstwo Produkcji Farmaceutycznej HASCO-LEK S.A. (Polska)

Question 11

What ATC class does Calcii dobesilas monohydricus belong to?

Accepted Answer

Calcii dobesilas monohydricus: ATC C05BX01. ATC is the WHO Anatomical Therapeutic Chemical classification — it groups drugs by organ system and pharmacological mechanism.

Calcii dobesilas monohydricus

User Reviews